Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because the usual routine of meetings, deadlines, and frantic scurrying about has predictably returned. This is especially true for those of you who took an extended break, yes? To cope, we are engaged in yet another routine — brewing cups of stimulation. Our choice today is hot-buttered rum. Rhymes with yum. Meanwhile, here are some tidbits to get you started. Best of luck today and please do keep in touch.

Last August, President Trump proudly proclaimed he had directed the Department of Veterans Affairs to buy “a lot” of esketamine, the first new major depression treatment with a novel mechanism to hit the U.S. market in decades. “Its results are incredible,” Trump said at a veterans convention in Kentucky. As of mid-December, the VA treated just 15 veterans across the country with the drug. The nasal spray, which was developed by Johnson & Johnson (JNJ) and named Spravato, was only available at seven of more than 1,200 agency facilities, STAT tells us.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!